Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Cardiovascular Outcomes Trial in Patients with Type 2 Diabetes
2018-003141-42Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and cardiac morbidity comparing Oral semaglutide + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to first occurrence of a major adverse cardiovascular event. Started May 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on 2018-003141-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003141-42.